Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2013 (2013), Article ID 676049, 9 pages
Research Article

Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

1Department of Epidemiology & Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100191, China
2Department of Ophthalmology, Peking University People’s Hospital, Beijing 100044, China
3Key Laboratory of Vision Loss & Restoration, Ministry of Education, Beijing 100044, China
4Institute of Immunoprophylaxis, Beijing Centers of Disease Control & Prevention, Beijing 100013, China

Received 20 June 2013; Accepted 22 July 2013

Academic Editor: Alfredo García-Layana

Copyright © 2013 Kai Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To identify the predictors of visual response to the bevacizumab treatment of neovascular age-related macular degeneration (AMD). Design. A cohort study within the Neovascular AMD Treatment Trial Using Bevacizumab (NATTB). Methods. This was a multicenter trial including 144 participants from the NATTB study. Visual outcomes measured by change in visual acuity (VA) score, proportion gaining ≥15 letters, and change in central retinal thickness (CRT) were compared among groups according to the baseline, demographic, and ocular characteristics and genotypes. Results. Mean change in the VA score was 9.2 ± 2.3 SD letters with a total of 46 participants (31.9%) gaining ≥15 letters. Change in median CRT was −81.5 μm. Younger age, lower baseline VA score, shorter duration of neovascular AMD, and TT genotype in rs10490924 were significantly associated with greater VA score improvement ( , , , and , resp.). Lower baseline VA score and TT genotype in rs10490924 were significantly associated with a higher likelihood of gaining ≥15 letters ( , and , resp.). Conclusions. Baseline VA and genotype of rs10490924 were both important predictors for visual response to bevacizumab at 6 months. This trial is registered with the Registration no. NCT01306591.